See what's next from Salugen.
Salugen's development pipeline is extremely robust and promising. The table below shows some of the key nutrigenomics products Salugen has in development. As a pioneer in individualized medicine, we are committed to reinvesting a significant percentage of our revenues back into research and development—a practice that is proving successful in bringing the world's first and only DNA-customized wellness products to market.
| Healthcare Concern |
Brand Name |
Anticipated Commercial Availability |
| Excess Cravings resulting in weight problems due to carbohydrate and sugar cravings |
GenoTrim™ |
GenoTrim - Pilot tested from March 2006
(Holland - The Netherlands) into December 2007 (USA)
Anticipated commercialization in early 2009
|
| Excess Cravings leading to stress induced skin disorders (psychodermatology) |
SpaGen |
SpaGen - Pilot tested November 2006
(US) to December 2007
Anticipated commercialization in 2009
|
| Excess Cravings leading to substance abuse, such narcotic, alcohol, and recreational drug abuse |
Haveos |
Haveos - Pilot test in April 2007 to December 2007
Anticipated commercialization in 2008
|
| Late Phase Development |
| Treatment protocols to support pain management and narcotic attenuation |
| Treatment protocol to support medically supervised weight loss |
| Treatment protocol to support health restoration during addiction treatment |
| Early Phase Development |
| Pre-Natal Vitamins |
| Pediatric Vitamins |
